Search results for "hemo"

showing 10 items of 5646 documents

Mitochondrial complex I impairment in leukocytes from type 2 diabetic patients.

2011

Diabetes is associated with oxidative stress. This study evaluated the rates of oxidative stress and mitochondrial impairment in type 2 diabetes patients. The study population consisted of 182 diabetic patients and 50 body-composition- and age-matched controls. We assessed anthropometric and metabolic parameters and mitochondrial function by evaluating mitochondrial oxygen (O2) consumption, reactive oxygen species (ROS) production, glutathione (GSH) levels, GSH/GSSG ratio, mitochondrial membrane potential, and mitochondrial complex I activity in polymorphonuclear cells from diabetes type 2 patients. We found an increase in waist circumference and augmented serum levels of triglycerides, pro…

medicine.medical_specialtymedicine.medical_treatmentType 2 diabetesMitochondrionBiologymedicine.disease_causeBiochemistryArticlechemistry.chemical_compoundInsulin resistancePhysiology (medical)Internal medicineDiabetes mellitusRotenonemedicineLeukocytesHumanschemistry.chemical_classificationReactive oxygen speciesElectron Transport Complex IInsulinMiddle Agedmedicine.diseaseMitochondriaOxygenOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2Glycated hemoglobinReactive Oxygen SpeciesOxidative stress
researchProduct

Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy

2020

Abstract Purpose To report a female patient of biclonal Lewis syndrome which consists of a trias: biclonal gammopathy of undetermined significance, paraproteinemic keratopathy in form of a brownish discoid opacification at the level of Descemet's membrane and hypercupremia. After several years there was a conversion to multiple myeloma. Systemic chemotherapy led to a complete remission of multiple myeloma and to a normalization of the copper level in the blood that lasted five years. The corneal opacification remained unchanged. Observations A currently 66-year-old woman suffered from biclonal Lewis syndrome. On both eyes there is a central discoid yellow-brownish discoloration in the Pre-D…

medicine.medical_specialtymedicine.medical_treatmentUnchanged corneal opacity after chemotherapyGastroenterology03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyChemotherapy-induced normal level of copper in serumInternal medicineMedicineAffinity of IgG to copper in Lewis syndromeCopper levelsProgressive anemiaMultiple myelomaLewis syndromeHypercupremiaChemotherapyBiclonal gammopathybusiness.industrySystemic chemotherapyHypercupremiaCorneal opacitymedicine.diseaseOphthalmologylcsh:RE1-994030221 ophthalmology & optometrybusinessDiscoid brownish opacification of Descemet membrane030217 neurology & neurosurgeryAmerican Journal of Ophthalmology Case Reports
researchProduct

Importance of Residual Renal Function in Continuous Ambulatory Peritoneal Dialysis: Its Influence on Different Parameters of Renal Replacement Treatm…

1999

<i>Objective:</i> To study the influence of residual renal function (RRF) on different parameters of the renal substitutive treatment offered by peritoneal dialysis. <i>Methods:</i> We analyzed the impact of RRF on dialysis dose, nutrition parameters, anemia and phosphocalcic metabolism in 37 patients with end-stage renal disease (ESRD) treated by continuous ambulatory peritoneal dialysis (CAPD). Analytical controls were done every 6 months after an initial assessment at the end of the first month of treatment. Multiple lineal regression models were used as the statistical method to analyze the influence of RRF on different theoretically dependent factors. RRF was ca…

medicine.medical_specialtymedicine.medical_treatmentUrologyRenal functionKidneyKidney Function Testsurologic and male genital diseasesPeritoneal dialysisPhosphorus metabolismHemoglobinsPeritoneal Dialysis Continuous AmbulatoryDialysis SolutionsmedicineHumansRetrospective Studiesbusiness.industryContinuous ambulatory peritoneal dialysisAnemiaPhosphorusRetrospective cohort studymedicine.diseaseSurgeryNutrition AssessmentRenal physiologyAmbulatoryLinear ModelsKidney Failure ChronicCalciumbusinessKidney diseaseNephron
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

The Impact of the Introduction of Innovative REDS Scale for the Evaluation of Central Tunnelled Catheter (CTC) Exit Site on Infection Prevention in L…

2021

Central tunneled catheter (CTC)-related infections are a leading cause of a catheter loss, thus being the source of significant morbidity and mortality. The study aims at evaluating the impact of the implementation of the innovative redness, edema, discharge and tenderness, symptoms (REDS) scale (devised by the authors) for the description of the tunnel condition on the frequency of infection in long-term catheter users. The same cohort of the 40 patients was observed for 4 years altogether: 2 years before and 2 years after REDS application. The results, as well as follow-up evaluation of participants, were compared. The 2-year cumulative incidence of the CTC exit site infection (ESI) dropp…

medicine.medical_specialtymedicine.medical_treatmentlcsh:Surgery030232 urology & nephrology030218 nuclear medicine & medical imaging03 medical and health sciencescentral tunneled catheter0302 clinical medicinemedicineInfection controlCumulative incidenceTunneled catheterOriginal ResearchExit sitecatheter-related infectionshemodialysisbusiness.industryvascular accesslcsh:RD1-811SurgeryCatheterCohortSurgeryHemodialysisbusinessBlood streamchronic kidney diseaseFrontiers in Surgery
researchProduct

Osteoblastic osteogenic sarcoma in a 13-month-old girl.

1994

Summary Osteosarcoma is exceptional in early periods of life. Therefore osteosarcomas involvingthe bones of the hand are extremely rare. We present a case of an osteogenic sarcoma involving the second metacarpal bone of a 13-month-old girl who has been remaining free of disease, after treatment — radial amputation and chemotherapy pre- and post-operative-, for a period of 10 years in the follow-up.

medicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectSecond metacarpal boneAmputation SurgicalPathology and Forensic MedicineFingersAntineoplastic Combined Chemotherapy Protocolsmedicinemedicine.boneHumansGirlmedia_commonChemotherapyOsteosarcomabusiness.industryInfantCell Biologymedicine.diseaseCombined Modality TherapySurgeryRadiographyAmputationOsteosarcomaFemaleSarcomaMetacarpusbusinessAfter treatmentFollow-Up StudiesPathology, research and practice
researchProduct

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Dise…

2020

Diabetes mellitus is a heterogeneous and dysmetabolic chronic disease in which the laboratory plays a fundamental role, from diagnosis to monitoring therapy and studying complications. Early diagnosis and good glycemic control should start as early as possible to delay and prevent metabolic and cardio-vascular complications secondary to this disease. Glycated hemoglobin is currently used as the reference parameter. The accuracy of the glycated hemoglobin dosage may be compromised in subjects suffering from chronic renal failure and terminal nephropathy, affected by the reduction in the survival of erythrocytes, with consequent decrease in the time available for glucose to attach to the hemo…

medicine.medical_specialtyobesitykidney diseaseglycated albumin cerebrovascular disease diabetes dyslipidemia obesity kidney disease therapy cardiovascular diseaselcsh:Medicine030209 endocrinology & metabolismDiseaseReview030204 cardiovascular system & hematologyNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinecardiovascular diseaseInternal medicineDiabetes mellitusMedicineGlycemictherapydiabetesbusiness.industrylcsh:RdyslipidemiaGeneral Medicinecardiovascular disease; cerebrovascular disease; diabetes; dyslipidemia; glycated albumin; kidney disease; obesity; therapymedicine.diseasecerebrovascular diseasechemistryBiomarker (medicine)glycated albuminGlycated hemoglobinbusinessDyslipidemiaKidney diseaseJournal of Clinical Medicine
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct